NCT00918814 is a Phase 2 clinical trial of LIPO-102 in Subcutaneous Adipose Tissue Reduction, sponsored by Neothetics, Inc.

Who is sponsoring NCT00918814?

NCT00918814 is sponsored by Neothetics, Inc.

What drugs are being tested in NCT00918814?

Interventions in NCT00918814: LIPO-102, Placebo.

What condition does NCT00918814 study?

NCT00918814 studies Subcutaneous Adipose Tissue Reduction.

Is NCT00918814 still recruiting?

NCT00918814 is currently completed. Last updated 17 February 2015.

Last reviewed 2015-02-17 · How we verify

NCT00918814

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Dose-Ranging and Dose Frequency Study Evaluating the Safety and Efficacy of LIPO-102 for the Reduction of Abdominal Subcutaneous Adipose Tissue

Completed Phase 2 Last updated 17 February 2015

What this trial tests

Phase 2 trial testing LIPO-102 in Subcutaneous Adipose Tissue Reduction in 54 participants. Completed in 1 February 2010.

Timeline

1 June 2009

Primary endpoint
1 February 2010

1 February 2010

Quick facts

Lead sponsor	Neothetics, Inc
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	54
Start date	1 June 2009
Primary completion	1 February 2010
Estimated completion	1 February 2010
Sites	2 locations across United States

Drugs / interventions tested

LIPO-102 — full drug profile →
Placebo

Conditions studied

Subcutaneous Adipose Tissue Reduction — all drugs for Subcutaneous Adipose Tissue Reduction →

Sponsor

Neothetics, Inc — full company profile →

Who can join

Adults 18 to 65, any sex, with Subcutaneous Adipose Tissue Reduction. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Safety: physical examinations, laboratory tests, AE assessment
Time frame: 4 weeks treatment and 4 weeks follow up

Sponsor's own description

Dose Ranging and Dose Frequency of LIPO-102

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Neothetics, Inc trials

Trials by the same sponsor.

NCT03005717 — Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00918814 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Neothetics, Inc
Last refreshed: 17 February 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00918814.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing